Piper Sandler analyst Matt O’Brien downgraded Globus Medical to Neutral from Overweight.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GMED:
- GMED Tanks on NuVasive Deal
- Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care
- Globus Medical sees FY23 net sales growth 7%-8%, consensus $1.12B
- Globus Medical sees FY22 net sales growth 6.8%, consensus $1.03B
- Globus Medical, NuVasive to combine in all-stock transaction